We designed a comprehensive 42‐marker mass cytometry panel to profile the peripheral blood samples from 57 patients diagnosed with advanced HER2‐negative breast cancer receiving anti‐PD‐1 combination therapy. Here, ERBB2 is linked to breast cancer.